https://www.resverlogix.com/upload/media_element/215/a92c88143fe9/2020-07-28-epigenetic-therapeutic-targets---wong.pdf
Type 2 Diabetics with CVD • Phase 3 trial BETonMACE2 is planned with 5,000 - 6,000 patients with T2DM, recent ACS and low HDL levels